Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study
Study Details
Study Description
Brief Summary
This single-blind prospective randomized study was designed to assess the efficacy and safety of the use of Surgicel® compared to the use of conventional surgical procedures (ligatures and bipolar electrocautery alone) to achieve hemostasis in thyroid surgery
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
patients who require a thyroidectomy will be enrolled after informed consent will begiven. Prior to thyroidectomy, patients will be randomized to two groups: 1) use of conventional surgical procedures to achieve hemostasis,i.e., ligatures and bipolar electrocauterization alone, and 2) use of oxidized cellulose patch (Surgicel©) in addition to classical methods (ligature; bipolar electrocautery). All anticoagulants will be discontinued 10 days prior to the operation, if this will not be possible the patient will be excluded. The investigators will perform the specified procedure in accordance with accepted clinical practice standards. At the end of the thyroidectomy, a meticulous hemostasis will be achieved. Before wound closure, the sealed affiliation envelopes will be opened and 1-2×2 cm oxidized cellulose patch will be placed over the thyroid bed depending on patient randomization. Next, a suction drain will be placed. The drains will be removed when the secretion volume/day will be less than 20 cc.
All operations will be performed under general anesthesia by three head and neck surgeons who had experience in thyroid surgery. Outcome measures will include duration of operation, hemodynamic variables on emergence (blood pressure and heart rate), volume of secretion in the drain, time to removal of wound drain, length of postoperative hospital stay, and incidence of postoperative complications, i.e. hemorrhage, transient hypoparathyroidism, wound infection, seroma, and recurrent laryngeal nerve palsy. Evaluation of the postoperative course and recording of data will be done by one surgeons blinded to the intervention (MA). Follow-up for this study will be ended one month after the surgery.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: CONVENTIONAL HEMOSTASIS patients for whom conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone) were used to achieve hemostasis |
|
| Active Comparator: SURGICEL patients will receive an oxidized cellulose patch (Surgicel®) in addition to conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone) |
Device: SURGICEL
Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
|
Outcome Measures
Primary Outcome Measures
- The primary endpoint of the study was the postoperative volume of wound drainage [1 WEEK]
Secondary Outcome Measures
- The secondary endpoints were events of bleeding requiring wound exploration under anesthesia [48 HOURS]
- duration of drain use [1 WEEK]
Other Outcome Measures
- hospitalization time [1 WEEK]
Eligibility Criteria
Criteria
Inclusion Criteria:
- All patients who required a thyroidectomy
Exclusion Criteria:
-
Unwilling or unable to consent
-
Age < 18 years
-
known allergy to oxidized cellulose
-
Inability to discontinue use of anticoagulants 10 days before surgery
-
Coagulopathy that could not be corrected
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Tel Aviv Medical Center | Tel Aviv | Israel | 66234 |
Sponsors and Collaborators
- Tel-Aviv Sourasky Medical Center
Investigators
- Principal Investigator: ZIV GIL, MD PhD, Tel-Aviv Sourasky Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
- Cotulbea S, Marin I, Golumba R, Barbos R, Epure V, Vălean M, Anghel I. [Our clinical management in treating seromucous otitis]. Rev Chir Oncol Radiol O R L Oftalmol Stomatol Otorinolaringol. 1988 Oct-Dec;33(4):259-64. Romanian.
- Quick MW, Naeve J, Davidson N, Lester HA. Incubation with horse serum increases viability and decreases background neurotransmitter uptake in Xenopus oocytes. Biotechniques. 1992 Sep;13(3):357-61.
- TASMC-ZG-AA-0633-CTIL